Unusual circulating anticoagulant in a patient with systemic lupus erythematosus.

Unusual circulating anticoagulant in a patient with systemic lupus erythematosus.
复制标题

系统性红斑狼疮患者的异常循环抗凝剂。

DOI:
10.1159/000207332
复制
发表时间:
1963
期刊:
影响因子:
2.4
通讯作者:
E. Torre López
E. Torre López
中科院分区:
医学4区
文献类型:
--
作者:
L. Sánchez;R. Lisker;E. Torre López

文献摘要

被引文献

相似文献

系统性红斑狼疮(SLE)是一种疾病,其中几种类型的自身免疫现象通常存在。其中,常见的有血小板减少性紫癜、溶血性贫血、循环抗凝剂;根据Mar-GOLIUS, Jackson AND Ratnoff(1)的研究,后一种并发症的发生率为13%。多数病例未出现临床出血表现;在进行常规实验室检查时,怀疑存在抗凝血剂。SLE中常见的一种循环抗凝剂会干扰凝血酶原向凝血酶的转化(2),因此凝血酶原时间异常。偶尔,它显示出抗凝血酶活性(3,4),只有一个病例报道它作为抗血栓塑蛋白原(5)。在与SLE相关的其他疾病状态中,如青霉素敏感反应、类风湿性关节炎、天疱疮等,虽然很少有抗凝剂干扰凝血活素形成的报道(6)。在这些病例中,抗血友病球蛋白的抑制作用已被证实。在这篇文章中描述的病人有一种循环抗凝血剂对凝血活素生成所必需的血清因子有活性。一些证据表明它对血浆凝血活素成分(PTC)起作用。
Systemic lupus erythematosus (SLE) is a disease in which several types of autoimmune phenomena are commonly present. Among them, thrombocytopenic purpura, hemolytic anemia, and circulating anticoagulants are commonly seen; according to Mar-GOLIUS, Jackson AND Ratnoff (1), the latter complication has a frequency of 13%. In the majority of cases there have not been clinical hemorrhagic manifestations; the existence of the anti coagulant has been suspected during the performance of routine laboratory procedures. The usual type of circulating anticoagulant found in SLE, interferes with the conversion of prothrombin to thrombin (2), and therefore the prothrombin time is abnormal. Occasionally, it has shown antithrombin activity (3, 4) and only one case has been reported in which it behaved as an anti-thromboplastinogen (5). In other disease states related to SLE, such as penicillin sensitivity reactions, rheumatoid arthritis, pemphigus, etc., though rarely, anticoagulants interfering with thromboplastin formation have been reported (6). In some of these cases, inhibition of the antihemophilic globulin has been demonstrated. The patient described in this paper had a circulating anti coagulant active against a serum factor necessary for thrombo plastin generation. Some evidence that it acted against the Plasma Thromboplastin Component (PTC) was obtained.